Fingolimod for multiple sclerosis

New England Journal of Medicine

Volumn 366, Issue 4, 2012, Pages 339-347

  Pelletier, Daniel ^a   Hafler, David A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; FINGOLIMOD; GLATIRAMER; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID; NATALIZUMAB; OLIGOCLONAL BAND; PLACEBO; RITUXIMAB; VIRUS ANTIBODY;

ACUTE DISEASE; ARTICLE; ASYMPTOMATIC DISEASE; ATRIOVENTRICULAR BLOCK; BASAL CELL CARCINOMA; BRADYCARDIA; BRAIN RADIOGRAPHY; BREAST CANCER; CARDIOVASCULAR DISEASE; CEREBROSPINAL FLUID EXAMINATION; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONVALESCENCE; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; GAIT; HUMAN; INTERNUCLEAR OPHTHALMOPLEGIA; JC VIRUS; LEG DISEASE; LOW DRUG DOSE; MELANOMA; MONOCULAR VISION; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLOR; PRIORITY JOURNAL; RETINA MACULA EDEMA; SIDE EFFECT; SINGLE DRUG DOSE; SKIN CANCER; SYSTOLIC BLOOD PRESSURE; TERATOGENICITY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

EID: 84856249964     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMct1101691     Document Type: Article

References (43)

1. Compston A. McAlpine's multiple sclerosis. Philadelphia: Elsevier/Churchill Livingstone, 2006.
2. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112:1419-28. (Pubitemid 20024212)
3. Tremlett H, Yinshan Z, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler 2008;14:314-24. (Pubitemid 351676426)
4. Sadovnick AD, Ebers GC, Wilson RW, Paty DW. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992;42:991-4.
5. Brønnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004;127:844-50. (Pubitemid 38478529)
6. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006;66: 1696-702. (Pubitemid 43964625)
7. Hafler DA, Slavik JM, Anderson DE, O'Connor KC, De Jager P, Baecher-Allan C. Multiple sclerosis. Immunol Rev 2005; 204:208-31. (Pubitemid 40460504)
8. Brinkmann V, Chen S, Feng L, Pinschewer D, Nikolova Z, Hof R. FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. Transplant Proc 2001; 33:530-1. (Pubitemid 32237498)
9. Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 2007;8:1295-301. (Pubitemid 350131168)
10. Pham TH, Okada T, Matloubian M, Lo CG, Cyster JG. S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity 2008;28:122-33.
11. Gräler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 2004;18:551-3.
12. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296:346-9. (Pubitemid 34303689)
13. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008;71:1261-7.
14. Mehling M, Lindberg R, Raulf F, et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 2010;75:403-10.
15. Zhou PJ, Wang H, Shi GH, Wang XH, Shen ZJ, Xu D. Immunomodulatory drug FTY720 induces regulatory CD4(+)CD25(+) T cells in vitro. Clin Exp Immunol 2009; 157:40-7.
16. Hu Y, Lee X, Ji B, et al. Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo. Mol Cell Neurosci 2011; 48:72-81.
17. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008;63:61-71. (Pubitemid 351240552)
18. Miron VE, Ludwin SK, Darlington PJ, et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol 2010;176:2682-94.
19. Yamagata K, Tagami M, Torii Y, et al. Sphingosine 1-phosphate induces the production of glial cell line-derived neurotrophic factor and cellular proliferation in astrocytes. Glia 2003;41:199-206. (Pubitemid 36262197)
20. Edsall LC, Pirianov GG, Spiegel S. Involvement of sphingosine 1-phosphate in nerve growth factor-mediated neuronal survival and differentiation. J Neurosci 1997;17:6952-60. (Pubitemid 27427874)
21. Harada J, Foley M, Moskowitz MA, Waeber C. Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J Neurochem 2004;88:1026-39. (Pubitemid 38199325)
22. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
23. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.
24. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
25. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904.
26. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-82. (Pubitemid 32488815)
27. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67:1242-9. (Pubitemid 44563835)
28. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-11. [Erratum, Lancet 2010;375:1436.]
29. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-81. (Pubitemid 41132342)
30. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-74. (Pubitemid 41132341)
31. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010; 68:295-303.
32. Le Page E, Leray E, Edan G. Longterm safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. Mult Scler 2011;17:867-75.
33. Espinosa PS, Berger JR. Delayed fingolimod- associated asystole. Mult Scler 2011;17:1387-9.
34. Medi-Span home page (http://www.medi-span.com).
35. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-40. (Pubitemid 44394919)
36. Comi G, O'Connor P, Montalban X, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2010;16:197-207.
37. Food and Drug Administration. FDA drug safety communication: safety review of a reported death after the first dose of multiple sclerosis drug Gilenya (fingolimod) (http://www.fda.gov/Drugs/DrugSafety/ucm284240.htm).
38. Koyrakh L, Roman MI, Brinkmann V, Wickman K. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant 2005;5:529-36. (Pubitemid 40313344)
39. Conzett KB, Kolm I, Jelcic I, et al. Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report. Arch Dermatol 2011;147:991-2.
40. Brinkmann V, Baumruker T. Pulmonary and vascular pharmacology of sphingosine 1-phosphate. Curr Opin Pharmacol 2006;6:244-50. (Pubitemid 44274746)
41. Gilenya (fingolimod) capsules medication guide. East Hanover, NJ: Novartis Pharmaceuticals, 2010.
42. FTY720 in patients with primary progressive multiple sclerosis (INFORMS) - ClinicalTrials.gov identifier: NCT00731692 (http://clinicaltrials.gov/ct2/ show/ NCT00731692).
43. Hartung HP, Aktas O. Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope. Ann Neurol 2009;66:429-32.